河北医学2024，Vol.30Issue(1)：45-49,5.DOI:10.3969/j.issn.1006-6233.2024.01.08
外周血中miR-34b表达水平对Ⅲb～Ⅳ期NSCLC患者靶向治疗效果及预后的评估价值分析
Evaluation of the Expression Level of miR-34b in Peripheral Blood for Targeted Treatment Effect and Prognosis in Stage Ⅲb-Ⅳ NSCLC Patients
摘要
Abstract
Objective:To explore the evaluation value of peripheral blood microRNA-34b(miR-34b)for targeted therapy effect and prognosis in patients with stage Ⅲb-Ⅳ non-small cell lung cancer(NSCLC).Methods:A total of 104 NSCLC patients who received targeted treatment from January 2020 to January 2022 were selected.According to the efficacy of targeted treatment,they were divided into the effective group(n= 40)and ineffective group(n=64).All patients were followed up for one year,and based on the prognosis,they were divided into the survival group(n=32)and death group(n=72).Real-time quantitative PCR was used to detect miR-34b in peripheral blood.The receiver operating characteristic curve(ROC)was employed to analyze the evaluation value of peripheral blood miR-34b expression level for the targeted treatment effect and prognosis of stage Ⅲb-Ⅳ NSCLC patients.Kaplan-Meier survival curve analysis was used to explore the relationship between different peripheral blood miR-34b expression levels and the prognosis of stage Ⅲb-ⅣNSCLC patients.Results:The peripheral blood miR-34b expression level in the effective group was higher than that in the ineffective group(P<0.05).The ROC curve showed that the AUC of peripheral blood miR-34b expression level in evaluating the targeted treatment effect of stage Ⅲb-Ⅳ NSCLC patients was 0.856(P<0.05).The peripheral blood miR-34b expression level in the survival group was higher than that in the death group(P<0.05).The ROC curve showed that the AUC of peripheral blood miR-34b expression level in evaluating the prognosis of stage Ⅲb-Ⅳ NSCLC patients was 0.916(P<0.05).The Log-rank test showed a statistically significant difference in survival rate between the miR-34b>2.16 group and miR-34b≤2.16 group(P<0.05).Conclusion:The expression level of peripheral blood miR-34b is associated with the targe-ted treatment effect and prognosis of stage Ⅲb-Ⅳ NSCLC patients.Detecting the expression level of peripher-al blood miR-34b is helpful for evaluating the targeted treatment effect and prognosis.关键词
非小细胞肺癌/微小RNA-34b/靶向治疗Key words
Non-small cell lung cancer/miRNA-34b/Targeted treatment引用本文复制引用
张亚鹏,任玉川,刘昭,吕晓燕,李永利..外周血中miR-34b表达水平对Ⅲb～Ⅳ期NSCLC患者靶向治疗效果及预后的评估价值分析[J].河北医学,2024,30(1):45-49,5.基金项目
山西省医学科技创新团队项目,(编号:2020TD15) （编号:2020TD15）
